%20.png?width=175&height=30&name=Main%20Logo%20(White-no%20transp)%20.png){kind=small}
CANDID EXPERT REACTIONS
to key neuroscience data releases, FDA announcements, and market activity
.png)
Introducing Neuroscience ACCUMIN Accumulated Insight
Powered by Psych Congress and the Neuroscience Education Institute
Giving neuroscience decision-makers a front-row seat to real-time, unbiased opinions and insights from an international panel of expert Thought Leaders.
Actionable insights to inform data generation, medical, marketing, and business strategies
Sponsor-blind to ensure all comments are candid and unbiased
Timed to immediately follow major data releases throughout the year
Exclusive Access with a
Neuroscience ACCUMIN Membership
An annual subscription to Neuroscience ACCUMIN includes exclusive access to:
- Attendance at Neuroscience ACCUMIN Congress Highlights events throughout the year
-
Neuroscience ACCUMIN Terminal™ with enduring archive of data readouts and discussion summaries
- News alerts with Neuroscience ACCUMIN Immediate Impact™ Scoring, the experts’ rapid response composite rating for new data releases and news developments
%20.png?width=175&height=30&name=Main%20Logo%20(White-no%20transp)%20.png "Main Logo (White-no transp)"){kind=small}
A FOCUS ON IMPACT
With thousands of updates occurring every year, Neuroscience ACCUMIN provides clear, timely, expert-driven guidance on what is impactful to inform strategic decision-making.
-
3,000+ currently investing in CNS product development
04 July 2023 01:00 AM
-
6,700 products with 1,350 unique mechanisms of action for CNS indications
04 July 2023 01:00 AM
-
15,000+ ongoing clinical trials involving CNS indications
04 July 2023 01:00 AM